ACE and COVID-19: Finally, ACE1 I/D genotyping may provide an opportunity for better risk stratification and help design further clinical trials reconsidering RAS-pathway antagonists in selected patients with COVID-19 to optimize intervention strategies and achieve more efficient targeted therapies.